Follow the Alamar Biosciences, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.3bn. The latest transaction was disclosed on 3 September 2026 (Attribution). Among the most active insiders: Qiming Corporate GP VI, Ltd.. All data is accessible without an account.
45
Insider Decl.
n/a
Thresholds
€7m
2 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Alamar Biosciences, Inc. Buy (bullish), based on 5 analysts. Average price target: US$33.40.
35Σ signal
Buys €7mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,120 of 29,062 companies
33.7
score / 100
Value
28
Quality
39
FCF yld-2.9%
Earn yld-1.4%
EV/EBITDA·
ROE·
Gross mgn56%
Net mgn-40%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
4,588,364 sharesClass B Common StockSEC:0001193125-26-164634:0
25 of 45 declarations
Acerca de Alamar Biosciences, Inc.
Alamar Biosciences, Inc. es una empresa centrada en el desarrollo de soluciones de diagnóstico e investigación en biotecnología. Cotiza en el mercado XNAS.